Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 20;9(1):e70081.
doi: 10.1002/hem3.70081. eCollection 2025 Jan.

Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

Amira Marouf  1 , Sammara Chaubard  2 , Raphaël Liévin  1 , Jean-Marie Michot  3 , Nicolas Molinari  4 , Julien Rossignol  5 , Doriane Cavalieri  6 , Camille Golfier  7 , Olivier Allangba  8 , Laure Philippe  9 , Benoît Tessoulin  10 , Adrien Chauchet  11 , Bénédicte Deau  12 , Lucie Oberic  13 , Jacques Vargaftig  14 , Aline Moignet  15 , Aline Clavert  16 , Rémy Dulery  17 , Gabriel Brisou  18 , Stéphanie Tardy  9 , Virginie Fataccioli  19 , Roch Houot  15 , René O Casasnovas  20 , Catherine Thieblemont  21 , Hervé Ghesquières  7 , Sylvain Carras  22 , Steven Le Gouill  14 , Guillaume Cartron  23 , Vincent Ribrag  3 , Morgane Cheminant  5 , Ambroise Marçais  5 , Felipe Suarez  5 , Aurélien Marabelle  24 , Olivier Tournilhac  25 , Gandhi Damaj  26 , Philippe Gaulard  19 , Laurence De Leval  27 , François Lemonnier  28 , Emmanuel Bachy  7 , Sylvie Chevret  29 , Olivier Hermine  1   5 , Lucile Couronné  1 , Arnaud Jaccard  2
Affiliations

Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

Amira Marouf et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier estimates of PFS (A) and OS (B) of patients from the aPD1 (red line) and historical (blue line) cohorts after propensity score matching.
See this image and copyright information in PMC

References

    1. de Mel S, Hue SS‐S, Jeyasekharan AD, Chng W‐J, Ng S‐B. Molecular pathogenic pathways in extranodal NK/T cell lymphoma. J Hematol Oncol. 2019;12:33. - PMC - PubMed
    1. Nagato T, Ohkuri T, Ohara K, et al. Programmed death‐ligand 1 and its soluble form are highly expressed in nasal natural killer/T‐cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66:877‐890. - PMC - PubMed
    1. Kataoka K, Miyoshi H, Sakata S, et al. Frequent structural variations involving programmed death ligands in Epstein‐Barr virus‐associated lymphomas. Leukemia. 2019;33:1687‐1699. - PMC - PubMed
    1. Kwong Y‐L, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T‐cell lymphoma failing l‐asparaginase. Blood. 2017;129:2437‐2442. - PubMed
    1. Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T‐cell lymphoma. J Hematol Oncol. 2018;11:15. - PMC - PubMed

LinkOut - more resources